MARKET

ACHV

ACHV

Achieve Life Sciences Inc
NASDAQ
3.580
+0.090
+2.58%
Pre Market: 3.650 +0.07 +1.96% 06:16 04/14 EDT
OPEN
3.480
PREV CLOSE
3.490
HIGH
3.580
LOW
3.420
VOLUME
441
TURNOVER
0
52 WEEK HIGH
6.03
52 WEEK LOW
1.950
MARKET CAP
190.60M
P/E (TTM)
-2.8560
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ACHV last week (0406-0410)?
Weekly Report · 1d ago
Weekly Report: what happened at ACHV last week (0330-0403)?
Weekly Report · 04/06 09:16
Achieve Life Sciences: The Recent Sell Off Skews The Outcomes
Seeking Alpha · 04/01 15:39
Weekly Report: what happened at ACHV last week (0323-0327)?
Weekly Report · 03/30 09:16
Achieve Life Sciences Maps High‑Stakes Path To 2027
TipRanks · 03/27 00:14
Achieve Life Sciences publishes corporate presentation; cytisinicline PDUFA set for June 20, 2026 for nicotine dependence smoking cessation treatment
Reuters · 03/26 21:52
Achieve Life Sciences: Maintaining 'Buy' On Upcoming PDUFA And Expansion Into Vaping Cessation
Seeking Alpha · 03/26 17:28
Achieve Life Sciences Flags FDA Observations While Pushing Launch To 2027 For Smoking Cessation Med
Benzinga · 03/26 12:58
More
About ACHV
Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company. The Company focuses on addressing the global smoking health and nicotine dependence epidemic through the development and commercialization of cytisinicline. It has completed two Phase III studies with cytisinicline for smoking cessation and one Phase II study with cytisinicline in vaping cessation. Cytisinicline is a naturally occurring, plant-based alkaloid. Cytisinicline is structurally similar to nicotine and has a dual-acting mechanism of action, being both a receptor agonist and antagonist. Cytisinicline is an investigational product candidate being developed for the treatment of nicotine dependence and has not been approved by the Food and Drug Administration for any indication in the United States. Cytisinicline acts as a partial agonist/antagonist, binding to alpha-4 beta-2 nicotinic receptors in the brain and is thought to have two potential consequences in treating nicotine dependence.

Webull offers Achieve Life Sciences Inc stock information, including NASDAQ: ACHV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACHV stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACHV stock methods without spending real money on the virtual paper trading platform.